Raymond James Initiates Coverage On Xilio Therapeutics with Outperform Rating, Announces Price Target of $16

Benzinga · 2d ago
Raymond James analyst Sean McCutcheon initiates coverage on Xilio Therapeutics (NASDAQ:XLO) with a Outperform rating and announces Price Target of $16.